News

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.
Novel subcutaneous electroencephalography systems are feasible and acceptable for monitoring seizures in the long term.
For patients 50 years and older at high cardiovascular risk without diabetes or prior stroke, an intensive SBP target seems cost-effective.